Released Nov 8, 2010, after the close
10-Q filed Nov 8, 2010, 39 days after period end · 0000950123-10-102510
Q3 2010 · 10-Q
Revenue$3.18M$3.18M no prior Q3 2009 on file+179.1% vs Q2 2010
Net Income-$2.47M-$2.47M no prior Q3 2009 on fileN/M vs Q2 2010
EPS Diluted$0.03$0.03 no prior Q3 2009 on file−75.0% vs Q2 2010
Gross Profit$2,119,000—
Operating Income-$2,848,000—
Operating Cash Flowderived-$9,680,000—
Free Cash Flowderived-$11,023,000—
Margins · derived
Gross margin66.6%
Operating margin-89.4%
Net margin-77.7%
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
no prior Q3 2009 on file
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR